According to the present invention, a composition that has high safety, can be continuously used for a long period, promotes production of VEGF and FGF7 involved in hair growth, and affords good prophylactic or improving effect on thinning hair or hair loss can be provided. The present invention relates to a composition for promoting hair thickening, containing one or more members selected from the group consisting of citrulline, tryptophan, glutamine, and ornithine, a composition for maintaining the anagen phase in the hair cycle and a composition for promoting VEGF production, each containing one or more members selected from the group consisting of citrulline, tryptophan, and glutamine, a composition for promoting transition from the telogen phase to the anagen phase in the hair cycle and a composition for promoting FGF7 production, each containing ornithine, and a composition for promoting normalization of the hair cycle, containing one or more members selected from the group consisting of citrulline, tryptophan, glutamine, and ornithine.

The present invention provides a method and a dietary composition for prevention and regulation of obesity capable of obtaining efficacy such as required appetite suppression or inducing satiety by having a positive effect on concentrations of neurotransmitters such as serotonin, dopamine, and norepinephrine which are the principle of a mechanism of appetite inhibitory drugs without prescription of medicines (Phentermine, Prozac, etc.) and further being used as an alternative diet and supplying a protein that is the most lack ingredient during diet. The dietary composition includes tryptophan, which is one amino acid, tyrosine, which is the other amino acid, Saint john's wort, which is one of herbs, and a whey protein as active ingredients.

The present invention provides a method and a dietary composition for prevention and regulation of obesity capable of obtaining efficacy such as required appetite suppression or inducing satiety by having a positive effect on concentrations of neurotransmitters such as serotonin, dopamine, and norepinephrine which are the principle of a mechanism of appetite inhibitory drugs without prescription of medicines (Phentermine, Prozac, etc.) and further being used as an alternative diet and supplying a protein that is the most lack ingredient during diet. The dietary composition includes tryptophan, which is one amino acid, tyrosine, which is the other amino acid, Saint john's wort, which is one of herbs, and a whey protein as active ingredients.

The present invention provides a method and a dietary composition for prevention and regulation of obesity capable of obtaining efficacy such as required appetite suppression or satiety by having a positive effect on concentrations of neurotransmitters such as serotonin, dopamine, and norepinephrine which are the principle of a mechanism of appetite inhibitory drugs without prescription of medicines (Phentermine, Prozac, etc.) and further being used as an alternative diet and supplying a protein that is the most lack ingredient during diet. The dietary composition includes tryptophan, which is one amino acid, tyrosine, which is the other amino acid, rhodiola, which is one herb, chamomile, which is the other herb, and a whey protein as active ingredients.

The present invention provides a method and a dietary composition for prevention and regulation of obesity capable of obtaining efficacy such as required appetite suppression or satiety by having a positive effect on concentrations of neurotransmitters such as serotonin, dopamine, and norepinephrine which are the principle of a mechanism of appetite inhibitory drugs without prescription of medicines (Phentermine, Prozac, etc.) and further being used as an alternative diet and supplying a protein that is the most lack ingredient during diet. The dietary composition includes tryptophan, which is one amino acid, tyrosine, which is the other amino acid, rhodiola, which is one herb, chamomile, which is the other herb, and a whey protein as active ingredients.

The present invention provides a method and a dietary composition for prevention and regulation of obesity capable of obtaining efficacy such as required appetite suppression or satiety by having a positive effect on concentrations of neurotransmitters such as serotonin, dopamine, and norepinephrine, and GLP-1 which are the principle of a mechanism of appetite inhibitory drugs without prescription of medicines (Phentermine, Prozac, Saxenda, etc.) and further being used as an alternative diet and supplying a protein that is the most lack ingredient during diet. The dietary composition includes tryptophan, which is one amino acid, tyrosine, which is the other amino acid, arginine, which is another amino acid, and a whey protein as active ingredients.

The present invention provides a method and a dietary composition for prevention and regulation of obesity capable of obtaining efficacy such as required appetite suppression or satiety by having a positive effect on concentrations of neurotransmitters such as serotonin, dopamine, and norepinephrine, and GLP-1 which are the principle of a mechanism of appetite inhibitory drugs without prescription of medicines (Phentermine, Prozac, Saxenda, etc.) and further being used as an alternative diet and supplying a protein that is the most lack ingredient during diet. The dietary composition includes tryptophan, which is one amino acid, tyrosine, which is the other amino acid, arginine, which is another amino acid, and a whey protein as active ingredients.

A vitamin for use by kidney patients in Stages 3, 4, 4a, 4b, and 5, who are not on dialysis, comprising administering daily a: low nitrogen diet; low nitrogen protein food comprising magnesium and/or calcium salts of alpha keto acids; and time released vitamin. The vitamin comprises the active ingredients of: Zinc; Selenium; Vitamins B1, B2, B6, B12, B5, E, and K2; Niacin; superoxide dismutase; catalase; glutathione and Folate; and excludes calcium, magnesium, phosphorus, sodium, manganese, fluoride, Vitamin D and K1. The low nitrogen food contains daily up to 300 mg of nitrogen; and at least five alpha keto analogues of magnesium and/or calcium salts of: leucine, isoleucine, methionine (MEMS-II), phenylalanine (PAMS-I), and valine. Methods of making and the chemical structures MEMS-II and the PAMS-I are disclosed. The treatment results in an increase of Glomerular Filtration Rate (GFR), a decrease in blood urea levels, and a decrease in creatinine levels.

A vitamin for use by kidney patients in Stages 3, 4, 4a, 4b, and 5, who are not on dialysis, comprising administering daily a: low nitrogen diet; low nitrogen protein food comprising magnesium and/or calcium salts of alpha keto acids; and time released vitamin. The vitamin comprises the active ingredients of: Zinc; Selenium; Vitamins B1, B2, B6, B12, B5, E, and K2; Niacin; superoxide dismutase; catalase; glutathione and Folate; and excludes calcium, magnesium, phosphorus, sodium, manganese, fluoride, Vitamin D and K1. The low nitrogen food contains daily up to 300 mg of nitrogen; and at least five alpha keto analogues of magnesium and/or calcium salts of: leucine, isoleucine, methionine (MEMS-II), phenylalanine (PAMS-I), and valine. Methods of making and the chemical structures MEMS-II and the PAMS-I are disclosed. The treatment results in an increase of Glomerular Filtration Rate (GFR), a decrease in blood urea levels, and a decrease in creatinine levels.

A low nitrogen protein food composition Albutrix™ for use by kidney patients in Stages 3, 4, 4a, 4b, and 5, who are not on dialysis, in a treatment program comprising administering daily a: low nitrogen diet; low nitrogen protein food comprising magnesium and/or calcium salts of alpha keto acids; and time released vitamin. The vitamin comprises the active ingredients of: Zinc; Selenium; Vitamins B1, B2, B6, B12, B5, E, and K2; Niacin; superoxide dismutase; catalase; glutathione and Folate; and excludes calcium, magnesium, phosphorus, sodium, manganese, fluoride, Vitamin D and K1. The low nitrogen food contains daily up to 300 mg of nitrogen; and at least five alpha keto analogues of magnesium and/or calcium salts of: leucine, isoleucine, methionine (MEMS-II), phenylalanine (PAMS-I), and valine. The treatment results in an increase of Glomerular Filtration Rate (GFR), a decrease in blood urea levels, and a decrease in creatinine levels.